Neutralizing antibodies to HIV-1 GP41 and their use

An isolated antibody, comprising:

• a VH comprising a HCDR1, a HCDR2, and a HCDR3 of the VH set forth as SEQ ID NO:
• 75, and a light chain variable region (VL) comprising a LCDR1, a LCDR2, and a LCDR3 of the VL set forth as SEQ ID NO:
• 6, wherein the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2, and the LCDR3 comprise the amino acid sequences set forth as:
• SEQ ID NOs:
• 7, 8, 77, 10, 11, and 12, respectively (10E8v4 S100cF CDRs);
• wherein the VH and the VL framework regions (FRs) further comprise amino acid sequences at least 90% identical to the VH and VL FRs of SEQ ID NOs:
• 75 and 6, respectively (10E8v4 S100cF);
• and
• wherein the antibody specifically binds to gp41 and neutralizes HIV-1.

An isolated antibody, comprising:

• a VH comprising a HCDR1, a HCDR2, and a HCDR3 of the VH set forth as SEQ ID NO:
• 75, and a light chain variable region (VL) comprising a LCDR1, a LCDR2, and a LCDR3 of the VL set forth as SEQ ID NO:
• 6, wherein the HCDR1, the HCDR2, the HCDR3, the LCDR1, the LCDR2, and the LCDR3 comprise the amino acid sequences set forth as:
• SEQ ID NOs:
• 7, 8, 77, 10, 11, and 12, respectively (10E8v4 S100cF CDRs);
• wherein the VH and the VL framework regions (FRs) further comprise amino acid sequences at least 90% identical to the VH and VL FRs of SEQ ID NOs:
• 76 and 6, respectively (10E8v4 V5R S100cF) and
• wherein the antibody specifically binds to gp41 and neutralizes HIV-1.